MC-1 (pyridoxal 5′-phosphate): novel therapeutic applications to reduce ischaemic injury

By Kandzari David E   Dery Jean-Pierre   Armstrong Paul W   Douglas Deborah A   Zettler Marjorie E   Hidinger G Karl-Gunnar   Friesen Albert D   Harrington Robert A  

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 11, 2005-11 ,pp. : 1435-1442

Informa Healthcare

Access to resources Recommend Favorite

Structure-Activity Relationships of Suramin and Pyridoxal-5'-phosphate Derivatives as P2 Receptor Antagonists

By  

Current Pharmaceutical Design, Vol. 8, Iss. 26, 2002-12 ,pp. : 2371-2399

Bentham Science Publishers

Access to resources Recommend Favorite

NF449, a novel picomolar potency antagonist at human P2X 1 receptors

By Hulsmann M.   Nickel P.   Kassack M.   Schmalzing G.   Lambrecht G.   Markwardt F.  

European Journal of Pharmacology, Vol. 470, Iss. 1, 2003-05 ,pp. : 1-7

Elsevier

Access to resources Recommend Favorite

LYP, a novel bestatin derivative, inhibits cell growth and suppresses APN/CD13 activity in human ovarian carcinoma cells more potently than bestatin

By Gao Jian-Jun  

Investigational New Drugs, Vol. 29, Iss. 4, 2011-08 ,pp. : 574-582

Springer Publishing Company

Access to resources Recommend Favorite

Pyridoxal 5'-Phosphate Enzymes as Targets for Therapeutic Agents

By  

Current Medicinal Chemistry, Vol. 14, Iss. 12, 2007-05 ,pp. : 1291-1324

Bentham Science Publishers

Access to resources Recommend Favorite